abstract：BACKGROUND:Chronic Myeloid Leukemia (CML) is characterized by the overproduction of BCR-ABL, a tyrosine kinase with constitutive activity, in which the majority of CML patients have e13a2 or e14a2 transcripts. Reckoned the possible associations between the hematologic and molecular features of the disease, a profound u...

journal_title：Leukemia research

authors： Ghalesardi OK,Khosravi A,Azizi E,Ahmadi SE,Hajifathali A,Bonakchi H,Shahidi M

更新日期：2021-01-19 00:00:00

abstract：:Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactiva...

journal_title：Leukemia research

authors： Djamai H,Berrou J,Dupont M,Kaci A,Ehlert JE,Weber H,Baruchel A,Paublant F,Prudent R,Gardin C,Dombret H,Braun T

更新日期：2020-12-13 00:00:00

abstract：:The role of interferon-gamma (IFN-γ) in Chronic Myelogenous/Myeloid Leukemia (CML) and in the treatment of CML remains unclear; specifically, the effect of IFN-γ on apoptosis. There is reported interplay between IFN-γ and glycogen synthase kinase-3 (GSK-3), a kinase which has been implicated in both cell death and, co...

journal_title：Leukemia research

authors： Kauffman MR,Nazemidashtarjandi S,Ghazanfari D,Allen AE,Reynolds NM,Faik A,Burdick MM,McCall KD,Goetz DJ

更新日期：2020-12-01 00:00:00

abstract：:We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK). The population included 40 female (63 %) and 23 male (37 %) patients, with a median age of 51 ye...

journal_title：Leukemia research

authors： Menghrajani K,Zhang Y,Famulare C,Devlin SM,Tallman MS

更新日期：2020-11-01 00:00:00

abstract：:Radiotherapy (RT)is considered the treatment of choice in patients with Extra-nodal marginal zone lymphoma (EMZL) at early stage, but the presence of late toxicities has been limited the acceptance. Recently, low doses of RT LDR) (2 x 2 Gy) and the use of limited fields has been observed that retain the efficacy but e...

journal_title：Leukemia research

authors： Aviles A,Cleto S

更新日期：2020-11-01 00:00:00

abstract：:There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

journal_title：Leukemia research

authors： Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

更新日期：2020-08-01 00:00:00

abstract：:Outcomes in patients with secondary acute myeloid leukemia (sAML) (including therapy related myeloid neoplasms and AML with myelodysplasia related changes (MRC)) are poor. Patients treated with hypomethylating agents (HMAs) for antecedent hematological malignancy (AHM) have suboptimal responses to induction chemothera...

journal_title：Leukemia research

authors： Talati C,Goldberg AD,Przespolewski A,Chan O,Ali NA,Kim J,Famulare C,Sallman D,Padron E,Kuykendall A,Lancet JE,Wang E,Tallman MS,Komrokji R,Sweet K

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:The skin is the common extranasal sites in extranodal natural killer (NK) / T - cell lymphoma, (ENKTL). However, data regarding cutaneous ENKTL are relatively scarce. Thus, we performed a large retrospective study to analyze clinical features and treatment outcomes of cutaneous ENKTL. PATIENTS AND METHODS:S...

journal_title：Leukemia research

authors： Jiang L,Li P,Quan Q,Chen P,Qiu H,Zhang B

更新日期：2020-01-01 00:00:00

abstract：PURPOSE:The study aims to develop a prognostic scoring system based on prognostic lncRNAs for acute myeloid leukemia (AML). METHODS:Based on lncRNA expression profiles downloaded from The Cancer Genome Atlas (TCGA), differentially expressed long noncoding RNAs (DELs) between good prognosis and bad prognosis samples we...

journal_title：Leukemia research

authors： Zeng H,Wu H,Yan M,Tang L,Guo X,Zhao X

更新日期：2020-01-01 00:00:00

abstract：:Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and...

journal_title：Leukemia research

authors： Liu M,Liao H,Chen Y,Lin Z,Liu Y,Zhang X,Chan HC,Sun H

更新日期：2019-11-01 00:00:00

abstract：:The risk of second malignant neoplasms (SMN) in chronic myeloid leukemia (CML) survivors remains unclear. We utilized the Surveillance, Epidemiology and End Results 18 (SEER 18) registries to evaluate the risk and subsequent outcomes of SMN in CML survivors. There were 3407 patients included. Of these, 170 (4.99%) dev...

journal_title：Leukemia research

authors： Jamy O,Sarmad R,Costa L

更新日期：2019-07-01 00:00:00

abstract：:The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CL...

journal_title：Leukemia research

authors： Spunarova M,Tom N,Pavlova S,Mraz M,Brychtova Y,Doubek M,Panovska A,Skuhrova Francova H,Brzobohata A,Pospisilova S,Mayer J,Trbusek M

更新日期：2019-06-01 00:00:00

abstract：:Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Co...

journal_title：Leukemia research

authors： King AC,Pappacena JJ,Tallman MS,Park JH,Geyer MB

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:Better risk-stratification of patients with chronic lymphocytic leukemia (CLL) and identification of subsets of ultra-high-risk (HR)-CLL patients are crucial in the contemporary era of an expanded therapeutic armamentarium for CLL. METHODS:A multivariate patient similarity network and clustering was applied...

journal_title：Leukemia research

authors： Turcsanyi P,Kriegova E,Kudelka M,Radvansky M,Kruzova L,Urbanova R,Schneiderova P,Urbankova H,Papajik T

更新日期：2019-04-01 00:00:00

abstract：PURPOSE:To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia. PATIENTS AND METHODS:We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolle...

journal_title：Leukemia research

authors： Medeiros BC,Othus M,Tallman MS,Sun Z,Fernandez HF,Rowe JM,Lazarus HM,Appelbaum FR,Luger SM,Litzow MR,Erba HP

更新日期：2019-03-01 00:00:00

abstract：:We compared 2-[fluorine-18] fluoro-2-deoxy-d-glucose PET-CT and contrast-enhanced computed tomography (CECT) in 62 consecutive patients with newly diagnosed Hodgkin Lymphoma (HL), aiming to provide evidences that may spare CECT from the staging procedures of HL patients. Among a total of 1448 nodal sites examined, dis...

journal_title：Leukemia research

authors： Panebianco M,Bagni O,Cenfra N,Mecarocci S,Ortu La Barbera E,Filippi L,Codacci-Pisanelli G,Biondi T,Laghi A,Cimino G

更新日期：2019-01-01 00:00:00

abstract：:Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...

journal_title：Leukemia research

authors： Naarmann-de Vries IS,Sackmann Y,Klein F,Ostareck-Lederer A,Ostareck DH,Jost E,Ehninger G,Brümmendorf TH,Marx G,Röllig C,Thiede C,Crysandt M

更新日期：2019-01-01 00:00:00

abstract：:Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL+ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGFβ1 both of which are produced from bone marrow stromal cells synerg...

journal_title：Leukemia research

authors： Ando N,Furuichi Y,Kasai S,Tamai M,Harama D,Kagami K,Abe M,Goi K,Inukai T,Sugita K

更新日期：2018-12-01 00:00:00

abstract：:Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. Since no standard therapeutic strategy currently exists for these diseases, we retrospectively evaluated the outcomes of allogeneic hematopoietic...

journal_title：Leukemia research

authors： Itonaga H,Ota S,Ikeda T,Taji H,Amano I,Hasegawa Y,Ichinohe T,Fukuda T,Atsuta Y,Tanizawa A,Kondo T,Miyazaki Y

更新日期：2018-12-01 00:00:00

abstract：:In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic int...

journal_title：Leukemia research

authors： Leitch HA,Buckstein R,Zhu N,Nevill TJ,Yee KWL,Leber B,Keating MM,St Hilaire E,Kumar R,Delage R,Geddes M,Storring JM,Shamy A,Elemary M,Wells RA

更新日期：2018-11-01 00:00:00

abstract：:Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/U...

journal_title：Leukemia research

authors： Miyazaki Y,Tuechler H,Sanz G,Schanz J,Garcia-Manero G,Solé F,Bennett JM,Bowen D,Fenaux P,Dreyfus F,Kantarjian H,Kuendgen A,Malcovati L,Cazzola M,Cermak J,Fonatsch C,Le Beau MM,Slovak ML,Santini V,Lübbert M,Macieje

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Chromosomal aberrations at the ETV6 gene locus on 12p13.2 are common in bone marrow samples involved by blastic plasmacytoid dendritic cell neoplasm (BPDCN). However, their pathogenic role, incidence in cutaneous BPDCN lesions, and clinical significance have not been assessed systematically. RESULTS:The stu...

journal_title：Leukemia research

authors： Tang Z,Li Y,Wang W,Yin CC,Tang G,Aung PP,Hu S,Lu X,Toruner GA,Medeiros LJ,Khoury JD

更新日期：2018-10-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i....

journal_title：Leukemia research

authors： Talati C,Sweet K

更新日期：2018-10-01 00:00:00

abstract：:Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

journal_title：Leukemia research

authors： Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-molecule inhibitor of JAK2 that has potential dose-dependent selectivit...

journal_title：Leukemia research

authors： Berdeja J,Palandri F,Baer MR,Quick D,Kiladjian JJ,Martinelli G,Verma A,Hamid O,Walgren R,Pitou C,Li PL,Gerds AT

更新日期：2018-08-01 00:00:00

abstract：:Essential thrombocythemia (ET) is an uncommon chronic myeloproliferative disorder with no cure. Patients with ET are at risk of different complications, and currently there are no optimal prognostic standards to predict severe post-diagnosis complications such as thrombosis and hemorrhage. In this study, we retrospect...

journal_title：Leukemia research

authors： Zhou D,Chen W,Cheng H,Qiao JL,Zhu LL,Li ZY,Xu KL

更新日期：2018-06-01 00:00:00

abstract：:Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...

journal_title：Leukemia research

authors： Zhu F,Khatri I,Spaner D,Gorczynski RM

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...

journal_title：Leukemia research

authors： Dholaria BR,Ayala E,Sokol L,Nishihori T,Chavez JC,Hussaini M,Kumar A,Kharfan-Dabaja MA

更新日期：2018-04-01 00:00:00

abstract：:The tumor microenvironment (TME) is critical to the longevity of tumor B cells in chronic lymphocytic leukemia (CLL). Bone marrow mesenchymal stem cells (BMMSCs) and the cytokines they produce including IL-6 are important components of the TME in CLL. We found BMMSCs supported the survival of CLL cells in vitro throug...

journal_title：Leukemia research

authors： Zhu F,McCaw L,Spaner DE,Gorczynski RM

更新日期：2018-03-01 00:00:00

abstract：:3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...

journal_title：Leukemia research

authors： Hu Z,Hu S,Ji C,Tang Z,Thakral B,Loghavi S,Medeiros LJ,Wang W

更新日期：2018-02-01 00:00:00

abstract：:The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KITwt); and AML wi...

journal_title：Leukemia research

authors： Strickland SA,Shaver AC,Byrne M,Daber RD,Ferrell PB,Head DR,Mohan SR,Mosse CA,Moyo TK,Stricker TP,Vnencak-Jones C,Savona MR,Seegmiller AC

更新日期：2018-02-01 00:00:00

abstract：:The present study explored the effects of Forkhead box Q1 (FOXQ1) on cell proliferation, cell cycle and apoptosis via the Sonic hedgehog (Shh) pathway in Natural killer/T-cell lymphoma (NKTCL). Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to detect FOXQ1 expression in 117 NKTCL patients and...

journal_title：Leukemia research

authors： Liu P,Chen L

更新日期：2018-01-01 00:00:00

abstract：:Myelodysplastic syndrome (MDS) are a heterogeneous group of clonal disease characterized by insufficiency of bone marrow, increase of apoptosis and increased risk of acute leukemia progression. Proteins related to the mitotic spindle (AURKA, AURKB, TPX2), to the mitotic checkpoint (MAD2, CDC20) and the regulation of t...

journal_title：Leukemia research

authors： Borges DP,Dos Santos AWA,Paier CRK,Ribeiro HL Júnior,Costa MB,Farias IR,de Oliveira RTG,França IGDF,Cavalcante GM,Magalhães SMM,Pinheiro RF

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. METHODS...

journal_title：Leukemia research

authors： Wong SA,Leitch HA

更新日期：2018-01-01 00:00:00

abstract：:Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide; such modifications are recommended to sustain therapy and maximize treatment duration. The aim of this retrospective case-control study was to de...

journal_title：Leukemia research

authors： DeZern AE,Binder G,Ni Q,McGuire M,Smith BD

更新日期：2017-12-01 00:00:00

abstract：:The treatment of acute leukemia is still challenging due in part to the development of resistance and relapse. This chemotherapeutics resistance is established by clonal selection of resistant variants of the cancer cells. Recently, a horizontal transfer of chemo-resistance among cancer cells via extracellular vesicle...

journal_title：Leukemia research

authors： Bouvy C,Wannez A,Laloy J,Chatelain C,Dogné JM

更新日期：2017-11-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a group of clonally-acquired blood disorders characterized by ineffective hematopoiesis leading to cytopenias. Red blood cell transfusions are an important component of supportive care in patients with MDS. Prolonged exposure to transfusions can lead to iron overload, which results ...

journal_title：Leukemia research

authors： Angelucci E,Cianciulli P,Finelli C,Mecucci C,Voso MT,Tura S

更新日期：2017-11-01 00:00:00

abstract：:Platelet transfusion refractoriness (PTR) is a major adverse event in the management of acute myeloid leukemia (AML). In a series of 897 adult patients with AML receiving intensive chemotherapy, we identified 41 patients (4.8%) with PTR. PTR was more frequently observed in parous women, patients with extra-medullary d...

journal_title：Leukemia research

authors： Comont T,Tavitian S,Bardiaux L,Fort M,Debiol B,Morère D,Bérard E,Delabesse E,Luquet I,Martinez S,Huguet F,Récher C,Bertoli S

更新日期：2017-10-01 00:00:00

abstract：:Although mutations in RNA splicing genes occur frequently in patients with clonal cytopenias of unknown significance (CCUS) and myelodysplastic syndromes (MDS), very often additional common myeloid gene driver mutations are present at diagnosis. Thus, the clinical significance of isolated mutations in the most commonl...

journal_title：Leukemia research

authors： Fleischman RA,Stockton SS,Cogle CR

更新日期：2017-10-01 00:00:00

abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...

journal_title：Leukemia research

authors： Verstovsek S,Mesa RA,Salama ME,Li L,Pitou C,Nunes FP,Price GL,Giles JL,D'Souza DN,Walgren RA,Prchal JT

更新日期：2017-10-01 00:00:00